Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 14/20 | 0.61 |
| ▸ | BCL6 | P41182 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | FPR2 | P25090 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4523983 | 0.91 | GRM5 (0.71) | GRM5BCL6BRD4AURKA | |
| SCHEMBL4518028 | 0.88 | GRM5 (0.60) | GRM5 | |
| SCHEMBL4512883 | 0.82 | GRM5 (0.83) | GRM5BCL6MAPT | |
| SCHEMBL4512281 | 0.81 | GRM5 (0.55) | GRM5BCL6MAPTTSHRNR4A1 | |
| SCHEMBL4528975 | 0.81 | GRM5 (0.44) | GRM5BRD4MAPTTSHR | |
| SCHEMBL4530571 | 0.81 | GRM5 (0.67) | GRM5BCL6MAPTTSHRNR4A1 | |
| SCHEMBL4519033 | 0.79 | GRM5 (0.64) | GRM5BCL6MAPTTSHRNR4A1 | |
| SCHEMBL4510461 | 0.78 | GRM5 (0.83) | GRM5BCL6 | |
| SCHEMBL4508247 | 0.76 | GRM5 (1.00) | GRM5BCL6MAPT | |
| SCHEMBL15201143 | 0.76 | BRD4 (0.47) | BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2009-11-19 | — | — | US | disclosed |
| CN-101460478-A | Novel bi-aryl amines | NOVARTIS AG (CH) | 2009-06-17 | — | — | CN | disclosed |
| EP-2004624-A1 | NOVEL BI-ARYL AMINES | Novartis AG (CH) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
| WO-2007113276-A1 | NOVEL BI-ARYL AMINES | NOVARTIS AG (CH) | 2007-10-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286827-A1 | NOVEL BI-ARYL AMINES | NAT1, MAOB, CYP2B6 | GRM5 3095/4885BCL6 2305/4885BRD4 435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.